SCHEMBL6314725

SCHEMBL6314725

Fc1ccccc1NCc1nnn[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 3/20 0.40
RAB9A P51151 3/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
NPC1 O15118 2/20 0.38
MITF O75030 1/20 0.38
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
ALOX12 P18054 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GAA P10253 2/20 0.37
TGFBR1 P36897 4/20 0.36
MAPK14 Q16539 3/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320333 0.81 ADRA2C (0.49) L3MBTL1KDM4ERAB9ALMNAALDH1A1
SCHEMBL6314967 0.81 ROCK2 (0.50) L3MBTL1KDM4ELMNAALDH1A1TDP1
SCHEMBL6321606 0.77 ROCK2 (0.53) L3MBTL1KDM4ERAB9ALMNAALDH1A1
SCHEMBL19283174 0.76 TAAR1 (0.50) RAB9AALDH1A1NPC1MAPTKMT2A
SCHEMBL3165410 0.71 TAAR1 (0.61) L3MBTL1KDM4ERAB9ALMNAALDH1A1
SCHEMBL6313181 0.71
SCHEMBL31402424 0.69 AR (0.41) KDM4ERAB9AALDH1A1NPC1MAPT
SCHEMBL10055034 0.69 HDAC1 (0.54) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL4982611 0.67 HSD17B10 (0.59) L3MBTL1KDM4ERAB9ALMNAALDH1A1
SCHEMBL2229796 0.67 L3MBTL1 (0.47) L3MBTL1RAB9AALDH1A1TDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments GLP1R, GIPR, GCGR L3MBTL1 1957/4885KDM4E 2371/4885RAB9A 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.